Billy Michael Chelliah Jebaraj

Dr. Billy Michael Chelliah Jebaraj


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
JQJialei Qi
Jialei Qi
SESascha Endres
Sascha Endres
DYDeyan Yordanov Yosifov
Deyan Yordanov Yosifov
ETEugen Tausch
Eugen Tausch
RDRashmi Priyadharshini Dheenadayalan
Rashmi Priyadharshini Dheenadayalan
SSStephan Stilgenbauer
Stephan Stilgenbauer

10 February 2022 in Blood
Verified
Journal Article
Closed access
PDF file
BJBilly Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj
AMAnnika Müller
Annika Müller
RDRashmi Priyadharshini Dheenadayalan
Rashmi Priyadharshini Dheenadayalan
SESascha Endres
Sascha Endres
PRPhilipp M. Roessner
Philipp M. Roessner
SSStephan Stilgenbauer
Stephan Stilgenbauer
Covalent Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib, have proven to be highly beneficial in the treatment of chronic lymphocytic leukemia (CLL). Interestingly, the off-target inhibition of IL-2-inducible T-cell kinase (ITK) by ibrutinib may also play a role in modulating the tumor microenvironment, potentially enhancing the treatment benefit. However, resistance to covalently binding BTK inhibitors can develop as the result of a mutation in cysteine 481 of BTK (C481S), which prevents irreversible binding of the drugs. In the present study we performed preclinical characterization of vecabrutinib, a next-generation noncovalent BTK inhibitor that has ITK-inhibitory properties similar to those of ibrutinib. Unlike ibrutinib and other covalent BTK inhibitors, vecabrutinib showed retention of the inhibitory effect on C481S BTK mutants in vitro, similar to that of wild-type BTK. In the murine Eμ-TCL1 adoptive transfer model, vecabrutinib reduced tumor burden and significantly improved survival. Vecabrutinib treatment led to a decrease in CD8+ effector and memory T-cell populations, whereas the naive populations were increased. Of importance, vecabrutinib treatment significantly reduced the frequency of regulatory CD4+ T cells in vivo. Unlike ibrutinib, vecabrutinib treatment showed minimal adverse impact on the activation and proliferation of isolated T cells. Lastly, combination treatment with vecabrutinib and venetoclax augmented treatment efficacy, significantly improved survival, and led to favorable reprogramming of the microenvironment in the murine Eμ-TCL1 model. Thus, noncovalent BTK/ITK inhibitors, such as vecabrutinib, may be efficacious in C481S BTK mutant CLL while preserving the T-cell immunomodulatory function of ibrutinib.

6 April 2023 in Blood
Verified
Journal Article
Open access
PDF file
QJQU JIANG
QU JIANG
JSJohanna Stachelscheid
Johanna Stachelscheid
JBJohannes Bloehdorn
Johannes Bloehdorn
APAlicja Pacholewska
Alicja Pacholewska
CAChristoph Markus Aszyk
Christoph Markus Aszyk
MHMarco Herling
Marco Herling
In chronic lymphocytic leukemia (CLL), epigenetic alterations are considered to centrally shape the transcriptional signatures that drive disease evolution and that underlie its biological and clinical subsets. Characterizations of epigenetic regulators, particularly histone-modifying enzymes, are very rudimentary in CLL. In efforts to establish effectors of the CLL-associated oncogene T-cell leukemia 1A (TCL1A), we identified here the lysine-specific histone demethylase KDM1A to interact with the TCL1A protein in B-cells in conjunction with an increased catalytic activity of KDM1A. We demonstrate that KDM1A is upregulated in malignant B-cells. Elevated KDM1A and associated gene expression signatures correlated with aggressive disease features and adverse clinical outcomes in a large prospective CLL trial cohort. Genetic Kdm1a knockdown (Kdm1a-KD) in Eμ-TCL1A mice reduced leukemic burden and prolonged animal survival, accompanied by upregulated p53 and pro-apoptotic pathways. Genetic KDM1A depletion also affected milieu components (T-, stromal, monocytic cells), resulting in significant reductions of their capacity to support CLL cell survival and proliferation. Integrated analyses of differential global transcriptomes (RNA-seq) and H3K4me3 marks (ChIP-seq) in Eµ-TCL1A vs. iKdm1aKD;Eµ-TCL1A mice (confirmed in human CLL) implicate KDM1A as an oncogenic transcriptional repressor in CLL by altering histone methylation patterns with pronounced effects on defined cell death and motility pathways. Finally, pharmacologic KDM1A inhibition altered H3K4/9 target methylation and revealed marked anti-B-cell-leukemic synergisms. Overall, we established the pathogenic role and effector networks of KDM1A in CLL, namely via tumor-cell intrinsic mechanisms and impacts in cells of the microenvironment. Our data also provide rationales to further investigate therapeutic KDM1A targeting in CLL.

5 June 2026 in Blood Advances
Verified
Journal Article
Open access
JQJialei Qi
Jialei Qi
WLWen Li
Wen Li
RDRashmi Priyadharshini Dheenadayalan
Rashmi Priyadharshini Dheenadayalan
DYDeyan Yordanov Yosifov
Deyan Yordanov Yosifov
CDCosima Drewes
Cosima Drewes
BJBilly Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj
Bruton tyrosine kinase inhibitors (BTKi) are successful in treatment of chronic lymphocytic leukemia (CLL), yet acquired resistance remains a challenge. In our study, REC-1 cells that acquired resistance to BTKi tirabrutinib by long-term treatment gained a splice-site mutation (SSM) c.2236-1G>T in PLCG2. Notably, a deletion spanning c.2236-23_2238 at the same splice site (SSD) was identified in CLL from a patient who had disease progression during ibrutinib therapy. These alterations resulted in the exon-skipped variant, ∆21, which exhibited enhanced phospholipase activity. PLCG2 SSM REC-1 exhibited increased anti-IgM-mediated calcium flux and resistance to BTK inhibition but retained sensitivity to PLCγ inhibitors. By analyzing additional primary CLL samples, we identified widespread expression of two additional exon-skipped variants, ∆22 and ∆20-22, independent of PLCG2 genetic alterations. The active ∆20-22, which is also described in PLCG2-associated immune dysregulation (PLAID), was predominantly present in CLL compared to healthy donor samples. Expression analysis in CLL cells isolated from patients before and after targeted treatments revealed a decrease in expression of ∆20-22 post-venetoclax (p = 0.02)while no change in expression was observed after ibrutinib treatment, indicating that these variants may persist in the presence of ibrutinib but might be lost in the absence of drug selection pressure. Our study reveals novel PLCG2 splice-site alterations and exon-skipped variants beyond the classical BTK or PLCG2 mutations, to have a potential role in BTKi resistance and inform treatment selection.

12 December 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
BJBilly Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj
SSStephan Stilgenbauer
Stephan Stilgenbauer
Summary: Resistance of chronic lymphocytic leukemia to BTK inhibitors poses a major clinical challenge; however, there is potential to overcome this obstacle by targeting the downstream protein kinase PKCβ using the novel inhibitor MS-553. By inhibiting PKCβ, MS-553 blocks B-cell receptor signaling and WNT/β-catenin and NF-κB functions, thereby inducing apoptosis in BTK inhibitor–resistant cells. See related article by Gordon et al., p. 85

6 October 2026 in Blood
Verified
Journal Article
Closed access
BJBilly Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj
ETEugen Tausch
Eugen Tausch
DYDeyan Yordanov Yosifov
Deyan Yordanov Yosifov
CSChristof Schneider
Christof Schneider
MFMoritz Fürstenau
Moritz Fürstenau
SSStephan Stilgenbauer
Stephan Stilgenbauer
Telomere length is a prognostic factor in chronic lymphocytic leukemia (CLL), yet its relevance under targeted therapies remains unclear. Here, we analyzed telomere length using qPCR in 917 samples from treatment-naïve CLL patients without TP53 aberrations enrolled in the GAIA/CLL13 trial comparing venetoclax-based combinations with rituximab (RV), obinutuzumab (GV), or obinutuzumab plus ibrutinib (GIV) versus chemoimmunotherapy (CIT). For CLL with TP53 aberrations, samples from 41 treatment-naïve patients receiving GIV in the CLL2-GIVe trial were analyzed. The median telomere lengths in GAIA/CLL13 and CLL2-GIVe were 4.0 kb (1.2-15.2) and 2.8 kb (1.4-14.0), respectively. A prognostic cutoff of 4.17 kb, based on GAIA/CLL13, was used for dichotomization into short and long telomeres. Within GAIA/CLL13, short telomeres significantly correlated with adverse clinical features including advanced Binet stage, high ECOG, high serum ß2-microglobulin and thymidine kinase levels, high lymphocyte count and large lymph nodes (all P<0.01). Among genetic features, short telomeres significantly associated with unmutated IGHV, del(11q), mutations in NOTCH1, SF3B1, XPO1, RPS15, EGR2 and NFKBIE, and karyotypic complexity (all P<0.01). Short telomeres were associated with shorter progression-free survival (PFS) within CIT, RV, GV, GIV in GAIA/CLL13 (all P<0.01) and in CLL2-GIVe (dichotomized by median; P=0.04), and impacted overall survival only in the CIT arm (P=0.024). Multivariable analysis suggested telomere length as an independent prognostic factor for PFS in the overall GAIA/CLL13 cohort. These findings propose telomere length as a prognostic marker for PFS in CLL patients receiving venetoclax-based first-line therapy and could be of relevance for risk stratification in the modern treatment era. NCT02950051